PHGUF (Pharming Group) Marketable Securities : $112.9 Mil (As of Dec. 2024)

View and export this data going back to . Start your Free Trial

What is Pharming Group Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Pharming Group's Marketable Securities for the quarter that ended in Dec. 2024 was $112.9 Mil.

Pharming Group's annual Marketable Securities increased from Dec. 2022 ($0.0 Mil) to Dec. 2023 ($151.7 Mil) but then declined from Dec. 2023 ($151.7 Mil) to Dec. 2024 ($112.9 Mil).

Pharming Group Marketable Securities Historical Data

The historical data trend for Pharming Group's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharming Group Marketable Securities Chart

Pharming Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Marketable Securities

Get a 7-Day Free Trial

151.68

112.95

Pharming Group Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Marketable Securities	Get a 7-Day Free Trial															151.68	150.08	113.18	111.10	112.95

Pharming Group Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Pharming Group (OTCPK:PHGUF) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Pharming Group Marketable Securities Related Terms

Thank you for viewing the detailed overview of Pharming Group's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharming Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (OTCPK:PHGUF) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

PHAR:USA PHARM:Netherlands 0QCO:UK PHG:Germany PHGN:Germany

Address

Darwinweg 24, Leiden, ZH, NLD, 2333 CR

Website

https://www.pharming.com

Pharming Group is a biopharmaceutical company. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome. In addition, the firm's development pipeline includes KL1333, a potential first-in-disease asset for mitochondrial DNA-driven primary mitochondrial diseases. The company's reportable segments are RUCONEST, which derives maximum revenue, Joenja, U.S., and Europe and the Rest of the World (RoW). Geographically, it derives maximum revenue from the United States.